Hunan Fangsheng Pharmaceutical (603998.SH): Indobufen tablets and others are expected to be selected for centralized procurement.

Hunan Fangsheng Pharmaceutical (603998.SH) announced that it recently participated in the bidding for the twelfth batch of national centralized bulk purchasing of medicines. According to the Announcement of the Proposed Selection Results for the Twelfth Batch of National Centralized Bulk Purchasing of Medicines released by the National Organization of Drug Joint Procurement Office on July 31, 2026, the company's product Indobufen tablets and the product Bisoprolol Amlodipine tablets from its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., are proposed to be selected for this centralized procurement. This centralized drug procurement is the twelfth batch of national medicines organized by the state. It requires medical institutions to prioritize the use of selected varieties in the centralized procurement and ensures the completion of the agreed procurement volume. The proposed selected products will see a certain degree of price reduction compared to their original prices. If the company subsequently signs procurement contracts and implements them, it will facilitate the rapid entry of the aforementioned products into the domestic sales market, increase market share, promote further development of the company's formulation business, enhance the company's brand influence, and have a positive impact on the companys future operations.